BiotechTube

ProHema-CB Transplant

Phase 1Terminated
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolic Disorders

Conditions

Metabolic Disorders

Trial Timeline

Jun 1, 2015 → Feb 1, 2017

NCT ID
NCT02354443

About ProHema-CB Transplant

ProHema-CB Transplant is a phase 1 stage product being developed by Fate Therapeutics for Metabolic Disorders. The current trial status is terminated. This product is registered under clinical trial identifier NCT02354443. Target conditions include Metabolic Disorders.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02354443Phase 1Terminated

Competing Products

20 competing products in Metabolic Disorders

See all competitors
ProductCompanyStageHype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
85
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
77
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomilDaiichi SankyoPhase 3
77
14C-labeled YM178Astellas PharmaPhase 1
33
TRC150094Torrent PharmaceuticalsPhase 1/2
41
LY518674Eli LillyPhase 2
52
Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
77
Metformin + PlaceboEli LillyApproved
85
Tirzepatide + SemaglutideEli LillyPre-clinical
23
LY3849891 + PlaceboEli LillyPhase 1
33
Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
85
RosuvastatinAstraZenecaPhase 3
77
Rosuvastatin + AtorvastatinAstraZenecaApproved
85
AZD2693 + PlaceboAstraZenecaPhase 1
33
RosuvastatinAstraZenecaPhase 3
77
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
77
rosuvastatinAstraZenecaApproved
85
EfinopegdutideMerckPhase 2
52
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)MerckPhase 2
52
Vericiguat + PlaceboMerckPhase 2
52

Other Products from Fate Therapeutics

ProHema-CB + Untreated CBPhase 2
44
ProTmune + Control ArmPhase 1/2
33
Single FT1050 treated UCB unitPhase 1
25
FT516 + Rituximab + Obinutuzumab + Cyclophosphamide + Fludarabine + IL-2 + BendamustinePhase 1
25
FT596 + Cyclophosphamide + Fludarabine + Rituximab + Obinutuzumab + BendamustinePhase 1
25